匹多莫德对慢性荨麻疹患者免疫状况的影响及其疗效

Clinical efficacy and the impact on immune status of pidotimod treatment for chronic urticaria

目的探讨匹多莫德治疗慢性荨麻疹的疗效以及对免疫状况的影响。方法 2013年1-12月确诊为慢性荨麻疹的155例患者分为对照组和试验组,对照组采用常规治疗,试验组在常规治疗的基础上加用匹多莫德治疗,连续给药4周。采用有效率、复发率、症状积分、不良反应率评价临床疗效,同时检测CD4+、CD8+水平。结果试验组、对照组的有效率分别为89.61%、79.49%,复发率分别为14.86%、54.05%,两组比较差异有统计学意义(P<0.05);治疗后,两组风团数目、持续时间均显著减少(P<0.05);治疗后,试验组与对照组相比,CD4+明显升高,CD8+明显下降,差异均有统计学意义(P<0.05)。结论匹多莫德可以改善慢性荨麻疹患者的临床症状,同时可改善患者免疫功能。

Objective To investigate the efficacy of pidotimod in the treatment of chronic urticaria and the effects on immune status. Methods A total of 155 patients were selected from January to December 2013. The patients were divided into control group and experimental group. Patients in control group received four weeks of conventional therapy,and patients in experimental group added pidotimod on the basis of conventional treatment. The effective rate,relapse rate,symptom scores,and adverse reaction rates were recorded for evaluating the clinical efficacy. Serum levels of CD4^＋,CD8^＋were measured. Results The total effective rates of control group and experimental group were89. 61%,79. 49%,and the relapse rates of the two groups were 14. 86%,54. 05%,there were significant differences between the two groups（ P〈0. 05）. After treatment,the number of wheals occurrences and duration was reduced in both two groups（ P〈0. 05）. After treatment,compared with control group,the level of CD4^＋in experimental group significantly increased（ P〈0. 05） and the CD8^＋level decreased（ P〈0. 05）. Conclusion Pidotimod capsules can significantly alleviate clinical symptoms,besides,it can improve the immune function of patients.